A cucumber extract marketed as Q-actin by IminoTech was found to support self-reported measures of joint comfort in a recent clinical study. The findings were published in Cureus.

In the trial, 80 adults with mild-to-moderate joint pain were instructed to consume either a placebo or 20 mg per day of Q-actin for 60 days. At baseline and days 15, 30, and 60, patients were assessed via WOMAC, Lequesne Functional Index, Brief Pain Inventory (BPI), and Pain Disability Index (PDI) questionnaires.

Significant improvements were observed by day 30, with continuous improvement observed over the remaining 30 days. By day 60, those in the Q-actin group experienced a 31.79% decrease in WOMAC scores (pain, stiffness, and function); a 32.39% reduction on the PDI (interference with work, sleep, mood, daily activities); and a 10.07% improvement on the Lequesne Functional Index (mobility, functional capacity).

“These results not only confirm Q-actin’s benefits, they extend them beyond previous osteoarthritis studies to adults with mild to moderate joint pain,” said Shil Kothari, CEO of IminoTech. “Consistent outcomes with a tiny 20 mg daily dose show Q-actin delivers reliable, everyday joint health benefits that consumers can feel.”

Q-actin is suitable for gummies, capsules, or stick packs, and can support everyday joint comfort in healthy populations, according to IminoTech. The ingredient is plant-derived and standardized to a bioactive called idoBR1.